Featured Press Releases

At AAD 2025, five-year data for BIMZELX® (bimekizumab-bkzx) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

At AAD 2025, five-year data for BIMZELX® (bimekizumab-bkzx) demonstrated sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

  • 17 Mar 2025

Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced...

Carterra unveils Carterra Ultra™, its most sensitive biosensor platform, advancing fragment and small molecule drug discovery

Carterra unveils Carterra Ultra™, its most sensitive biosensor platform, advancing fragment and small molecule drug discovery

Optune Lua® by Novocure Receives CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer

Optune Lua® by Novocure Receives CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

  • Eton Pharmaceuticals
  • 04 Mar 2026
FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

  • 3T Biosciences
  • 03 Mar 2026
Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

  • Matricelf Ltd.
  • 27 Feb 2026
ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

  • ARUP Laboratories
  • 26 Feb 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.